-
Innovation Ranking
Innovation Ranking – Surface Oncology Inc
Surface Oncology Inc (Surface Oncology) is an immuno-oncology company. It develops novel antibody therapies for the treatment of cancer. The company’s product portfolio includes SRF388, to treat various diseases like renal cell carcinoma, hepatocellular carcinoma, and non-small-cell lung cancer; SRF617, to treat various tumors like gastric cancer, prostate cancer, PD-(L)1 relapsed cancer, and pancreatic cancer. Surface Oncology also provides SRF114, NZV930 and GSK4381562 antibodies. It also carries out research and development activities and pre-clinical studies. The company has entered two...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AO-176 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AO-176 in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AO-176 in Relapsed Multiple Myeloma Drug Details: AO-176 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AO-176 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AO-176 in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AO-176 in Refractory Multiple Myeloma Drug Details: AO-176 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AO-176 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AO-176 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AO-176 in Endometrial Cancer Drug Details: AO-176 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AO-176 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AO-176 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AO-176 in Non-Small Cell Lung Cancer Drug Details: AO-176...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AO-176 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AO-176 in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AO-176 in Fallopian Tube Cancer Drug Details: AO-176 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AO-176 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AO-176 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AO-176 in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AO-176 in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AO-176 in Malignant Pleural Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AO-176 in Malignant Pleural Mesothelioma Drug Details: AO-176 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AO-176 in Papillary Thyroid Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AO-176 in Papillary Thyroid Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AO-176 in Papillary Thyroid Cancer Drug Details: AO-176 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AO-176 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AO-176 in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AO-176 in Peritoneal Cancer Drug Details: AO-176 is under development for...